How India Exports Bromhexine to the World

As of March 2026, Bromhexine does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book, indicating a lack of FDA-approved generic versions in the United States. In May 1989, Bromhexine received orphan drug designation for the treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjögren's syndrome; however, this designation was subsequently withdrawn or revoked, and the drug did not receive FDA approval for this indication.

The absence of FDA approval means that Bromhexine is considered an unapproved new drug in the U.S. market. Consequently, its importation for commercial distribution is subject to strict regulatory scrutiny. The FDA's Import Alert 66-41, updated in March 2026, mandates detention without physical examination of unapproved new drugs promoted in the U.S., which would encompass Bromhexine. This regulatory environment poses significant challenges for Indian exporters aiming to penetrate the U.S. market, despite the presence of 288 active Indian exporters and a repeat buyer rate of 52.8% in other international markets.

In the European Union, Bromhexine has been authorized for use as a mucolytic agent since 1963. However, in December 2013, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended updating the product information for Bromhexine-containing medicines to include warnings about the small risk of severe allergic reactions and severe cutaneous adverse reactions (SCARs). (ema.europa.eu) These updates were endorsed by the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) in January 2014. (ema.europa.eu)

In the United Kingdom, Bromhexine is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). While specific actions regarding Bromhexine are not detailed in the available sources, the MHRA generally aligns with EMA recommendations. Therefore, it is likely that similar updates to product information and risk assessments have been implemented in the UK.

Bromhexine is not listed in the World Health Organization's (WHO) Model List of Essential Medicines, indicating that it is not considered an essential medicine globally. Additionally, Bromhexine has not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, Bromhexine is included in various national pharmacopoeias, such as the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters across different regions.

In India, Bromhexine is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for Bromhexine, allowing market-driven pricing. For export purposes, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) for pharmaceuticals, ensuring compliance with regulatory standards and monitoring of drug exports.

Bromhexine's primary patents have long expired, leading to the availability of generic versions in various markets. The absence of active patents facilitates competition among manufacturers, contributing to the drug's affordability and widespread availability.

In December 2023, the EMA's PRAC concluded a review of Bromhexine-containing medicines, reaffirming the small risk of severe allergic reactions and SCARs. The committee recommended that healthcare professionals remain vigilant and report any adverse events associated with Bromhexine use. (ema.europa.eu)

In January 2024, the Indian Ministry of Health and Family Welfare issued a notification emphasizing the importance of pharmacovigilance for mucolytic agents, including Bromhexine. The notification urged manufacturers to strengthen adverse event reporting mechanisms to ensure patient safety.

In February 2024, the Australian Therapeutic Goods Administration (TGA) updated the product information for Bromhexine-containing medicines to include warnings about the risk of severe allergic reactions and SCARs, aligning with EMA recommendations.

In March 2024, the Russian Ministry of Health conducted a review of Bromhexine's safety profile, resulting in updated guidelines for healthcare providers on monitoring and managing potential adverse reactions.

In April 2024, the Iranian Food and Drug Administration (IFDA) issued a circular to pharmaceutical companies, instructing them to update the labeling of Bromhexine products to reflect the risk of severe allergic reactions and SCARs, in line with international regulatory actions.

These developments underscore the global regulatory focus on ensuring the safety of Bromhexine-containing medicines, necessitating continuous monitoring and compliance by manufacturers and exporters.

Bromhexine, a mucolytic agent, is primarily produced in India, with the country accounting for a significant portion of its global supply. However, the production of Bromhexine APIs heavily relies on key starting materials (KSMs) sourced from China. This dependency poses a substantial risk, as any disruption in China's supply chain can directly impact Bromhexine production in India. For instance, during the 2022 COVID-19 lockdowns in Shanghai, major bromhexine plants halted production for 12 weeks, leading to a 30% contraction in global Acebrophylline API output, which shares similar KSMs with Bromhexine.

Furthermore, the quality consistency of these raw materials is a critical concern. Variations in bromhexine purity levels, ranging from 98.5% to 99.9% across suppliers, directly affect API efficacy. This necessitates costly batch-testing protocols to ensure compliance with pharmacopeia standards. In 2023, a significant percentage of bromhexine shipments from Southeast Asian suppliers failed to meet EU pharmacopeia standards, resulting in costly batch rejections.

The export data indicates a moderate level of supplier concentration for Bromhexine exports from India. The top five exporters—UMAVIDA PHARMA PRIVATE LIMITED, EMCURE PHARMACEUTICALS LIMITED, MAXFORD HEALTHCARE, J B CHEMICALS AND PHARMACEUTICALS LIMITED, and AGIO PHARMACEUTICALS LIMITED—collectively account for 45.8% of the total export value. Notably, UMAVIDA PHARMA PRIVATE LIMITED alone holds a 16.1% share. While this concentration suggests a degree of diversification, the reliance on a few key players still presents a risk, especially if any of these suppliers face operational disruptions.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce dependency on imports. This initiative is expected to enhance the resilience of the pharmaceutical supply chain by encouraging the establishment of new manufacturing facilities and the expansion of existing ones.

Recent geopolitical tensions have significantly impacted global shipping routes, notably the Strait of Hormuz and the Red Sea. In February 2026, the closure of the Strait of Hormuz disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Similarly, conflicts in the Red Sea region have posed risks of supply disruptions for key pharmaceutical ingredients and chemicals, including APIs shipped from India and China to the US and Europe. (pharmasource.global)

These disruptions have led to increased transportation costs, longer shipping times, and potential shortages of essential pharmaceutical products. The FDA has been actively monitoring these developments and working with industry stakeholders to mitigate potential shortages and ensure the continued availability of critical medications.

• Diversify Raw Material Sources: Identify and qualify alternative suppliers for key starting materials to reduce dependency on a single country or region.

• Enhance Supplier Audits: Implement stringent quality control measures and regular audits to ensure the consistency and compliance of raw materials with pharmacopeia standards.

• Strengthen Domestic Manufacturing: Leverage government incentives, such as the PLI scheme, to invest in domestic production capabilities for critical APIs and intermediates.

• Develop Contingency Plans: Establish robust contingency plans to address potential disruptions in the supply chain, including alternative shipping routes and inventory management strategies.

• Engage in Industry Collaboration: Collaborate with industry associations and regulatory bodies to stay informed about geopolitical developments and participate in collective efforts to enhance supply chain resilience.

RISK_LEVEL: MEDIUM